Garo Armen - Protagenic Therapeutics Chairman of the Board

PTIX Stock  USD 0.52  0.01  0.96%   

Chairman

Dr. Garo H. Armen, Ph.D. is Chairman of the Board of the Company. He is one of our founders and joined us in September 2004. Garo H. Armen is Chairman and Chief Executive Officer of Agenus Inc., a biotechnology company he cofounded in 1994. From mid2002 through 2004, he also served as Chairman of the Board of directors of the biopharmaceutical company Elan Corporationrationration, plc, which he successfully restructured. Prior to Agenus Inc., Dr. Armen established Armen Partners, a money management firm specializing in biotechnology and pharmaceutical companies, and was the architect of the widely publicized creation of the Immunex Lederle oncology business in 1993. Earlier, he was a senior vice president of research at Dean Witter Reynolds, having begun his career on Wall Street as an analyst and investment banker at EF Hutton. In 2002, Dr. Armen founded the Children of Armenia Fund, a nonprofit organization dedicated to significantly rebuilding and revitalizing impoverished rural Armenian towns to provide immediate and sustainable benefits to children and youth. He received the Ellis Island Medal of Honor in 2004 for his humanitarian efforts, and received the Sabin Humanitarian Award from the Sabin Vaccine Institute in 2006 for his achievements in biotechnology and progressing medical research. Dr. Armen was also the Ernst Young 2002 New York City Biotechnology Entrepreneur of the Year, and received a Wings of Hope Award in 2005 from The Melanoma Research Foundation for his ongoing commitment to the melanoma community since 2016.
Age 71
Tenure 8 years
Professional MarksPh.D
Address 149 Fifth Avenue, New York, NY, United States, 10010
Phone212 994 8200
Webhttps://www.protagenic.com
Armen received a PhD in physical chemistry from the Graduate Center, City University of New York, after which he worked as a research fellow at Brookhaven National Laboratories in Long Island, NY.

Garo Armen Latest Insider Activity

Tracking and analyzing the buying and selling activities of Garo Armen against Protagenic Therapeutics stock is an integral part of due diligence when investing in Protagenic Therapeutics. Garo Armen insider activity provides valuable insight into whether Protagenic Therapeutics is net buyers or sellers over its current business cycle. Note, Protagenic Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Protagenic Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Protagenic Therapeutics Management Efficiency

The company has return on total asset (ROA) of (0.9017) % which means that it has lost $0.9017 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.0636) %, meaning that it created substantial loss on money invested by shareholders. Protagenic Therapeutics' management efficiency ratios could be used to measure how well Protagenic Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.21 in 2024. Return On Capital Employed is likely to rise to -1.17 in 2024. At this time, Protagenic Therapeutics' Total Current Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 12 M in 2024, whereas Total Assets are likely to drop slightly above 4.1 M in 2024.
Protagenic Therapeutics currently holds 655.25 K in liabilities with Debt to Equity (D/E) ratio of 0.04, which may suggest the company is not taking enough advantage from borrowing. Protagenic Therapeutics has a current ratio of 19.08, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Protagenic Therapeutics' use of debt, we should always consider it together with its cash and equity.

Similar Executives

Found 1 records

CHAIRMAN Age

Peter LuoAdagene
58
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. Protagenic Therapeutics (PTIX) is traded on NASDAQ Exchange in USA. It is located in 149 Fifth Avenue, New York, NY, United States, 10010 and employs 1 people. Protagenic Therapeutics is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Protagenic Therapeutics Leadership Team

Elected by the shareholders, the Protagenic Therapeutics' board of directors comprises two types of representatives: Protagenic Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Protagenic. The board's role is to monitor Protagenic Therapeutics' management team and ensure that shareholders' interests are well served. Protagenic Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Protagenic Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Robert MD, Chief Director
Garo Armen, Chairman of the Board
MD CFA, CFO Secretary
David Lovejoy, Scientific Officer
Andrew Slee, Chief Officer

Protagenic Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Protagenic Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Protagenic Stock Analysis

When running Protagenic Therapeutics' price analysis, check to measure Protagenic Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagenic Therapeutics is operating at the current time. Most of Protagenic Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagenic Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagenic Therapeutics' price. Additionally, you may evaluate how the addition of Protagenic Therapeutics to your portfolios can decrease your overall portfolio volatility.